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Increased knowledge of the biology of synaptic function has led to the development of novel cognitive-enhancing
therapeutic strategies with the potential for increased efficacy and safety. This editorial highlights a diverse array of
approaches currently being explored to target cognitive dysfunction due to aging and/or Alzheimer’s disease.
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Aging is the single most significant risk factor for
Alzheimer’s disease (AD). As we age, certain cognitive
functions decline, a process known as cognitive aging.
Cognitive function begins to decline in young adulthood,
possibly as early as in the second or third decade of life.
While there is ongoing debate as to how the trajectory
of normal cognitive aging relates to the pathological pro-
gression of AD, the development of novel cognitive-
enhancing therapies is vital for improving function and
quality of life for individuals suffering from cognitive im-
pairment due to cognitive aging or AD.
Currently available US Food and Drug Administration
(FDA)-approved drugs for AD either inhibit acetyl-
cholinesterase (AChE) or target the N-methyl-D-aspar-
tate receptor to improve cognitive function. Many other
cognitive-enhancing strategies are under investigation.
Caffeine, B vitamins and docosahexaenoic acid are ex-
amples of natural compounds that have been reported
to improve cognition, although it is important to note
that these agents can affect people in different ways and
more scientific research is needed [1-3]. Exercise, medi-
tation and other dietary factors have also been proposed
to enhance cognition, although the data are far from
conclusive [3,4]. Here, we highlight several exciting
pharmacological therapeutic strategies that may both
enhance cognitive function and offer potential to slow
disease progression in AD patients. These strategies are* Correspondence: DShineman@alzdiscovery.org
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© BioMed Central Ltd.2013explored in more detail in this special issue on ‘Cogni-
tive enhancers for aging and Alzheimer’s disease’.
Metabotropic glutamate receptor subtype 5
Memory impairment may be due to an imbalance of in-
hibitory and excitatory neurotransmission. The excita-
tory neurotransmitter, glutamate, is decreased in the
hippocampus of AD patients. Glutamate can modulate
excitatory postsynaptic currents via the metabotropic
glutamate receptor subtype 5 (mGlu5). Increasing the
activation of mGlu5 may offer an exciting new thera-
peutic strategy to enhance cognitive function in AD pa-
tients. Jeff Conn’s group at Vanderbilt University has
developed a series of mGlu5 positive allosteric modula-
tors for AD, schizophrenia and other neurological condi-
tions [5]. As opposed to direct activation of the mGlu5
receptor, positive allosteric modulators boost the re-
sponse of this receptor to glutamate and enhance synap-
tic plasticity while avoiding unwanted side-effects seen
with direct activation.
Nicotinic acetylcholine receptor
The neuronal nicotinic acetylcholine receptor (nAChR)
is another important target for cognitive-enhancing ther-
apies. The nAChRs are expressed in the hippocampus, a
key brain area implicated in cognitive dysfunction with
both aging and Alzheimer’s disease. nAChRs function
both presynaptically to regulate neurotransmitter release
and postsynaptically where they can activate intracellular
signaling cascades involved in learning and memory. Ac-
tivation of the α7nAChR subtype with small-molecule
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learning and memory across multiple cognitive domains
in rodents, monkeys, and humans (reviewed in [6]).
nAChRs – in particular, the α7nAChR – may also be in-
volved in amyloid beta-induced neurotoxicity. The US
FDA-approved drug galantamine is a putative allosteric
activator of nAChRs in addition to its AChE-inhibitory
profile, and therefore may actually be neuroprotective
and slow disease progression in patients [7,8].
M1 Muscarinic acetylcholine receptors
In addition to nicotinic agonists, M1 muscarinic agonists
have the potential to boost cognition and slow disease
progression. Postsynaptic M1 muscarinic acetylcholine
receptors play a major role in hippocampal-based mem-
ory and learning. These receptors are relatively spared
from degeneration in AD, so even when AChE inhibitors
lose their efficacy because the disease has caused pre-
synaptic degeneration and decreasing acetylcholine
levels, MI selective muscarinic agonists may continue
to produce a cognitive benefit, although specificity is
critical. In addition, M1 muscarinic agonists also have
the potential to affect multiple disease pathologies in-
cluding amyloid-beta and phosphorylated tau through
regulation of a-disintegrin and metalloprotease 10/17
and of glycogen synthase kinase 3β activity, respectively
(reviewed in [9]).
5-Hydroxytryptamine receptors
In contrast to direct cholinergic stimulation, another
potential therapeutic avenue is indirect cholinergic
stimulation through 5-hydroxytryptamine (5-HT)6 re-
ceptors. Evidence from cellular and animal models sug-
gests that 5-HT6 receptors may enhance cholinergic
signaling through glutamatergic and gamma-aminobutyric
acidergic pathways (reviewed in [10]). Both agonist and
antagonist ligands of this poorly understood G-protein
-coupled receptor have been shown to enhance cognition
in preclinical rodent models. These findings may be
explained by differential receptor coupling to multiple Gα
subunits or by the potential for agonist and antagonist
5-HT6 ligands to act on distinct neuronal populations.
Several ligands currently in early-phase clinical trials show
promise as symptomatic treatments for AD and are also
being evaluated in combination with AChE inhibitors. Of
note, Lundbeck’s 5-HT6 receptor antagonist Lu AE58054
met its primary endpoint in a recent clinical study [11].
Norepinephrine
Modulation of the noradrenergic system has the poten-
tial to be both a symptomatic and disease-modifying
therapeutic strategy. The noradrenergic neurons of the
locus coeruleus exhibit selective vulnerability during
aging, with a significant loss of these cells and a decreasein norepinephrine observed in mild cognitive impairment
and AD patients (reviewed in [12]). Norepinephrine is an
excitatory neurotransmitter that also has anti-inflammatory
properties. Regulators of norepinephrine levels are clinically
approved for use in neuropsychiatric disorders and have
demonstrated positive symptomatic and disease-modifying
effects in preclinical AD studies [13]. In clinical studies,
the norepinephrine reuptake inhibitor atomoxetine
improved overall global cognition in a small study of
Parkinson’s disease patients. A phase IIa study in
amnestic mild cognitive impairment patients is cur-
rently being led by Allan Levey (Emory University)
and colleagues to determine the effects of atomoxetine
on biomarkers of AD pathology, inflammation and
cognitive function (ClinicalTrials.gov: NCT01522404).
This provides an exciting opportunity for repurposing
of a US FDA-approved drug, which if successful will
accelerate the drug’s availability for AD patients.Cyclic adenosine monophosphate
Although the hippocampus is the brain area most fre-
quently discussed in relation to AD, the prefrontal cor-
tex is critical for higher-level cognitive function and is
sensitive to aging (reviewed in [14]). Within this brain
area, cAMP signaling is increased with aging leading to
an increased opening of hyperpolarization-activated cyc-
lic nucleotide-gated potassium channels and a reduced
activity of neurons involved with working memory. This
cAMP prefrontal cortex pathway has been successfully
targeted to improve cognitive function in attention-deficit
hyperactivity disorder and other disorders using guanfacine,
an alpha-2A adrenergic receptor agonist that was originally
approved by the US FDA for anti-hypertensive effects.
The ability of guanfacine to enhance cognitive function
in older people with cognitive aging has recently been
tested in a clinical trial by Christopher Van Dyck, based
in large part on research by Amy Arnsten and others at
Yale University [15].Conclusion
There is currently lack of consensus in the field on the
neurochemical and pathological differences between
cognitive aging and AD. We do not yet know whether
cognitive aging is a discrete clinical syndrome or simply
an earlier stage in the continuum of AD. Many of
the therapeutic approaches described above as well
as other cognitive enhancer strategies (including inhibi-
tors of phosphodiesterases, monoamine oxidase B, hista-
mine H3 receptor, histone deacetylases, among others)
target general mechanisms associated with learning
and memory and would probably benefit individuals
suffering from both cognitive aging and AD. Novel
cognitive-enhancing therapeutics will also be useful as
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differences between normal cognitive aging and AD.
As these cognitive-enhancing therapeutics enter clin-
ical testing, the need for quantitative and sensitive bio-
markers to track cognitive function for both patient
selection and for monitoring therapeutic response is
critical. Combining cognitive testing paradigms with
physical biomarkers such as functional imaging and elec-
troencephalography may provide greater insight into
underlying disease mechanisms and increase the poten-
tial effectiveness of these trials. These biomarkers will
also help to elucidate differences or similarities between
normal cognitive aging and AD. Ultimately, a greater un-
derstanding of the pathobiology of cognitive dysfunction
with aging will accelerate the development of effective
cognitive enhancers for both cognitive aging and AD.
Note: This article is part of a series on Traumatic Brain Injury, edited
by Robert Stern. Other articles in this series can be found at
http://alzres.com/series/traumaticbraininjury.Abbreviations
AChE: Acetylcholinesterase; AD: Alzheimer’s disease; FDA: Food and Drug
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